New synthetic opioids: Part of a new addiction landscape.


Journal

Neuroscience and biobehavioral reviews
ISSN: 1873-7528
Titre abrégé: Neurosci Biobehav Rev
Pays: United States
ID NLM: 7806090

Informations de publication

Date de publication:
11 2019
Historique:
received: 16 02 2018
revised: 14 05 2018
accepted: 12 06 2018
pubmed: 16 9 2018
medline: 4 8 2020
entrez: 16 9 2018
Statut: ppublish

Résumé

Synthetic opioids (SO) are a major risk for public health across the world. These drugs can be divided into 2 categories, pharmaceutical and non-pharmaceutical fentanyls. A new generation of SO has emerged on the drug market since 2010. North America is currently facing an opioid epidemic of morbi-mortality, caused by over-prescription of opioids, illegally diverted prescribed medicines, the increasing use of heroin and the emergence of SO. Furthermore, this opioid crisis is also seen in Europe. SO are new psychoactive substances characterized by different feature such as easy availability on the Internet, low price, purity, legality, and lack of detection in laboratory tests. They have not been approved or are not recommended for human use. Opioid misuse is associated with somatic and psychiatric complications. For many substances, limited pharmacological information is available, increasing the risk of harmful adverse events. Health actors and the general population need to be clearly informed of the potential risks and consequences of the diffusion and use of SO.

Identifiants

pubmed: 30217656
pii: S0149-7634(18)30114-3
doi: 10.1016/j.neubiorev.2018.06.010
pii:
doi:

Substances chimiques

Analgesics, Opioid 0
Synthetic Drugs 0
Fentanyl UF599785JZ

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

133-140

Informations de copyright

Copyright © 2018 Elsevier Ltd. All rights reserved.

Auteurs

Laurent Karila (L)

Addiction Research and Treatment Center, Paul Brousse Hospital, Paris-Sud University, INSERM U1000, Villejuif, France. Electronic address: laurent.karila@aphp.fr.

Maude Marillier (M)

Addictogilance center (CEIP-A), Fernand Widal Hospital, Paris, France.

Boris Chaumette (B)

Montreal Neurological Institute and Hospital, Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.

Joel Billieux (J)

Addictive and Compulsive Behaviours Lab, Institute for Health and Behaviour, University of Luxembourg, Esch-sur-Alzette, Luxembourg.

Nicolas Franchitto (N)

Addiction center, Centre Hospitalo-Universitaire Toulouse-Purpan, Toulouse, France; UMR1027, Université de Toulouse, UPS, INSERM, Toulouse, France.

Amine Benyamina (A)

Addiction Research and Treatment Center, Paul Brousse Hospital, Paris-Sud University, CESP, Villejuif, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH